Evidence map›Paper›PMID 31265884›Full record

ArticleInternational journal of pharmaceutics2019

Development of microparticles for controlled release of resveratrol to adipose tissue and the impact of drug loading on particle morphology and drug release.

Christopher Isely, Michael A Hendley, Kendall P Murphy, Safaa Kader, Prakasam Annamalai, Esmaiel Jabbari, R Michael Gower

Open access · greenAbstract read
In one paragraph

Article in International journal of pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Christopher IselyDepartment of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA.
Michael A HendleyBiomedical Engineering Program, University of South Carolina, Columbia, SC 29208, USA.
Kendall P MurphyDepartment of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA.
Safaa KaderDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA.
Prakasam AnnamalaiDepartment of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA.
Esmaiel JabbariDepartment of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA.
R Michael GowerDepartment of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA; Biomedical Engineering Program, University of South Carolina, Columbia, SC 29208, USA. Electronic address: gowerrm@mailbox.sc.edu.
University of South Carolina · US

Funding

Targeting NMDA Receptors and Brain Estradiol to Rescue Memory in Aging FemalesP20GM109091 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI RONINSON, IGOR B · 2014 to 2024
$25.2M
Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
TISSUE BIOREPOSITORY COREP30GM103336 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BERGER, FRANKLIN G. · 2013 to 2017
$5.4M
NIGMS NIH HHS P20 GM103641NIGMS NIH HHS P20 GM109091NIGMS NIH HHS P30 GM103336
6 · The paper itself

Abstract

Resveratrol is a small molecule produced by various plants with a remarkable range of beneficial functions in animals. One of these is stimulating signaling pathways in adipose tissue that protect against obesity. Unfortunately, resveratrol suffers from poor bioavailability that inhibits its accumulation in target tissues, including fat, thus hindering the realization of its therapeutic potential. To address this, we are developing biodegradable microparticles as drug depots for controlled release of resveratrol within fat. In this study, resveratrol was encapsulated into poly(lactide-co-glycolide) microparticles using an oil-in-water emulsion/solvent evaporation technique. The oil phase consisted of resveratrol and poly(lactide-co-glycolide) dissolved in a mixture of dichloromethane and ethanol; meanwhile, the aqueous phase contained poly(vinyl alcohol) as the emulsifier. Increasing ethanol's volume ratio increased resveratrol's solubility in the oil phase and particle drug loading. The maximal loading achieved was 65 µg/mg (6.5%) and occurred when the ethanol to dichloromethane ratio was 1:3. Under these conditions, particles exhibited ruffled surfaces, which resulted in variable drug release over the first three days of a six-week release assay. By decreasing resveratrol and ethanol in the oil phase and increasing poly(vinyl alcohol) in the aqueous phase, smooth particles were achieved, but they suffered a 15-25-fold decrease in drug loading depending on size. Small particles exhibited higher drug loading and burst drug release compared to larger particles because of their higher specific surface area. Utilizing mild chemistry, we functionalized poly(vinyl alcohol) with fluorescein isothiocyanate and demonstrated that encapsulation of resveratrol in the particle decreases the amount of fluorescent polymer on the particle surface, suggesting resveratrol displaces the emulsifier during particle formation. Taken together, resveratrol can be encapsulated into poly(lactide-co-glycolide) microparticles, but it accumulates at the particle surface impacting drug loading, surface roughness, and drug release.

Indexed as

3T3-L1 CellsAdipose TissueAnimalsDelayed-Action PreparationsDrug LiberationFluorescein-5-isothiocyanateMiceParticle SizePolylactic Acid-Polyglycolic Acid CopolymerPolyvinyl AlcoholResveratrolDelayed-Action PreparationsFluorescein-5-isothiocyanatePolylactic Acid-Polyglycolic Acid CopolymerPolyvinyl AlcoholResveratrolAdipose tissueDrug deliveryMicroparticlePoly(lactide-co-glycolide)Resveratrol

Identifiers

PMID31265884
PMCPMC6709855
OpenAlexW2955780716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.